Lower respiratory infections (LRIs) accounted for three million deaths worldwide in 2016, the leading infectious cause of mortality. The "gold standard" for investigation of bacterial LRIs is culture, which has poor sensitivity and is too slow to guide early antibiotic therapy.
Lower respiratory infections (LRIs) are the third most common cause of death globally and are the leading infectious cause, accounting for three million deaths worldwide in 2016 (http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). They can be subdivided into chest infection, community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), bronchitis and bronchiolitis (https://www.nice.org.uk/guidance/cg191).
Morbidity and mortality rates vary dependent on infection site, pathogen and host factors. In the UK, CAP accounts for approx. 29 ,000 deaths per annum and it is estimated that HAP accounts for approx. 36 ,000 deaths in the US per annum 1 However, a wide range of pathogens, including viruses, can cause these infections, meaning that microbial diagnosis and treatment are challenging.
Every year in the UK NHS treat 16 million people with antibiotics for respiratory tract infections (https://www.nice.org.uk/guidance/cg191/documents/pneumonia-final-scope2).
Initial treatment for severe LRIs, particularly HAP, often involves empirical broad-spectrum antibiotics. Guidelines recommend that such therapy should be refined or stopped after two to three days, once microbiology results become available [7] [8] [9] , but this is often not done, if the patient is responding well or the laboratory has failed to identify a pathogen. Such extensive 'blind' use of broad-spectrum antibiotics is wasteful and constitutes poor stewardship, given that many patients are infected with a virus or a susceptible pathogen.
Antimicrobial over-treatment leads to disruption of the gut flora, promoting the risk of overgrowth by resistant bacteria and of Clostridium difficile 10, 11 .
There is an urgent need for rapid microbiological diagnostics to ensure swift tailored treatment and to reduce prolonged broad-spectrum antibiotic therapy. "Gold standard" culture and susceptibility testing is not fit for purpose in this regard, owing to slow turnaround times (48-72 hours) and low clinical sensitivity 1, 2, 7, 12 . Molecular methods have the potential to overcome this limitations, as highlighted by the Chief Medical Officer and O'Neill reports (2016) , identifing pathogens and their antibiotic resistance profiles within a few hours, thereby allowing early therapeutic refinement, and supporting effective antibiotic stewardship 13, 14 . However, molecular methods present their own challenges. Nucleic acid amplification tests (including PCR) are rapid and highly specific/sensitive, but uncommon agents and antibiotic resistances cannot readily be sough, given the limits on multiplexing 8, 15, 16 . 17 .
There is also a constant need to update these PCR-based methods to include emerging resistance genes and mutations 9, 18, 19 .
Metagenomic sequencing based approaches, which make no presumptions about the organisms and resistance genes that may be present, have the potential to overcome the shortcomings of both culture and PCR, by combining speed with comprehensiveness 20 . Nanopore sequencing (Oxford Nanopore Technologies, ONT) has particular potential for rapid diagnostic applications, with the advantage of real-time data acquisition and analysis 21, 22 as compared with other NGS platforms (e.g. Illumina) where sequencing can take up to 48hrs before analysis can begin 23 . Nanopore sequencing has previously been used to identify viral and bacterial pathogens from clinical samples using targeted approaches and in proof-of-concept studies using samples with high pathogen loads (e.g. urinary tract infection) 22, 24, 25 . Respiratory specimens present a greater challenge, owing to the variable pathogen load, the presence of commensal respiratory tract flora, and the high ratio of host:pathogen nucleic acids present (up to 10 5 :1 in sputum).
It is possible to apply rapid metagenomics to respiratory samples, as demonstrated by Pendleton et al. (2017) , who used nanopore sequencing, without host cell depletion, to samples from two bacterial pneumonia patients. The vast majority of reads, however, were of human origin, with only one and two nanopore reads aligned to the infecting pathogens, P. aeruginosa and S. aureus, respectively 26 . It seems likely that their method could be improved by depletion of host DNA but, although commercial kits and published methods are available for this purpose 27, 28 , they do not perform well in complex respiratory samples and improved methods are required. Accordingly, we developed and optimised a state-of-the-art nanopore-sequencing based clinical metagenomics pipeline for the investigation of bacterial LRIs capable of removing up to 99.99% host nucleic acid from clinical respiratory samples, enabling pathogen and antibiotic resistance gene identification within six hours.
RESULTS

Pilot method testing
The first 'Pilot' iteration of the metagenomics pipeline, the pilot method, was tested on respiratory samples from 40 patients with suspected bacterial LRI. Overall, this method was 91.2% sensitive (95% CI; 75.2-97.7%) and 83.3% specific (95% CI; 36.5-99.1%), not counting additional organisms in culture-positive samples as false positives (Table 1) Table 1 ).
Organisms reported by routine microbiology were not detected in 3/40 samples by the Pilot method. Two of these cases were mixed infections where one organism was missed by the Pilot method -specifically, S. pneumoniae and H. influenzae were not detected in P3 and P37 respectively -and S. aureus was not detected in P34.
Optimisation experiments
Efforts were made to reduce major errors (8.8% false negative rate) by improving bacterial cell lysis, thereby improving assay performance. We also sought to reduce the sample-toresult turnaround time.
Improving bacterial cell lysis
A sample pre-treatment step was introduced, involving either bead-beating or an enzyme cocktail, to increase the lysis of difficult-to-lyse organisms. Two culture-positive sputa were used for optimisation experiments, one containing S. aureus (Gram-positive) and one containing P. aeruginosa (Gram-negative). Neither pre-treatment affected the yield of P. aeruginosa DNA, but the enzyme cocktail increased the amount of S. aureus DNA detected by approx. 4-fold and bead-beating achieved a 20-fold increase compared with the pilot method, as determined by qPCR ( Supplementary Table 2a ). Accordingly, bead-beating was introduced as a standard pre-treatment in the Optimised method.
Reducing turnaround time
Prior to optimisation, the host DNA depletion method took approx. 1.5 hrs. Removal of the second DNase treatment and reducing the number of washes shortened this to 50 min without affecting the degree of human DNA depletion compared to the pilot method (average: >10 3 fold; ) ( Supplementary Table 2a ). Time could also be saved by reducing the library preparation PCR extension time from six to four minutes. Comparison of the microbial community profile after sequencing showed no difference in the top three most abundant species and only a small reduction in average fragment length (<400bp) between libraries produced with four and six minute extension times ( Supplementary Table 2b ). This enabled MinION library preparation to be completed within two hours and a half (reduced from 3.5 hours), giving an overall turnaround time of under four hours prior to DNA sequencing.
Limit of detection
The limit of detection (LoD) of the method was determined using an uninfected 'normal respiratory flora' (NRF) sputum sample spiked with serial ten-fold dilutions of S. aureus and E. coli cultures at known cell densities. The LoD was defined as the fewest cells required for the identification of the infecting 'pathogen' using the analysis pipeline as follows: ³1% microbial reads identified using WIMP and an alignment score ³20. The LoD was determined to be 10,000 (10 4 ) cells for both E. coli and S. aureus (Supplementary Table 3 ).
Mock community detection
The Optimised method was tested in triplicate on a panel of common respiratory pathogens spiked into NRF sputum (~10 8 cfu/ml per pathogen) to determine whether the saponin human DNA depletion method led to inadvertent loss of any bacterial DNA. We observed no bacterial DNA loss (average ΔCq <1) for any organisms (E. coli, H. influenzae, K. pneumoniae, P. aeruginosa, S. aureus and S. maltophilia) tested except S. pneumoniae where there was a 5.7-fold loss, (average ΔCq 2.52) between depleted and undepleted samples ( Supplementary Table 4 ).
Optimised method evaluation
The optimised method was then tested on 41 respiratory samples from patients with suspected bacterial LRIs. A maximum of 10 4 fold depletion of human DNA (average 10 3 fold; range 4.8-18,054 fold) was observed between depleted and undepleted samples ( Table 2 ).
The overall sensitivity of the refined method for the detection of respiratory pathogens was 96.6% (95% CI, 80.4-99.8%), specificity was 41.7% (95% CI, 16.5-71.4%), again not counting additional organisms in culture-positive samples as false positives ( Table 3 ). The turnaround time from sample to result was approx. 6 hours (including 2 hours MinION sequencing) (Supplementary Table 5 ).
The pathogenic organism reported by routine microbiology was detected together with an additional pathogen (not reported by culture) in eight samples: K. pneumoniae in S5, P. aeruginosa in S7, M. catarrhalis in S14 and S39, S. aureus in S29 and S. pneumoniae in S8 and S15 (Table 2 ). Up to two potentially pathogenic bacteria were also observed in seven samples reported as NRF/no significant growth (NSG) by routine microbiology, (S10, 11, 12, 21, 28, 31 and 32) . H. influenzae and S. pneumoniae in S10 and S21; S. pneumoniae in S11 and S28; M. catarrhalis and H. influenzae in S12; H. influenzae in S31 and E. coli in S32.
Only one pathogenic organism reported by routine microbiology was not detected using the Optimised method. Specifically, S9 was reported as a mixed infection with P. aeruginosa and E. coli whereas only E. coli was detected by metagenomics. There were two other mixed infections reported by routine microbiology, both involving S. aureus together with H.
influenzae (S27 and S41), and both organisms were detected using the Optimised method.
Antibiotic resistance analysis
The collection of samples tested using the optimised method had low rates of antibiotic resistance, as determined by routine testing ( Supplementary table 6 ). Across the 33 cultivated organisms, just 38 instances of resistance or intermediate resistance to tested antibiotics were recorded (Table 4 ), and some of these overlapped (e.g. two S. aureus were resistant to oxacillin, flucloxacillin and penicillin).
Of these 38, five could be discounted as resistance inherent in the cultured species (e.g. to penicillins in K. pneumoniae and co-amoxiclav in Serratia marcescens). Of the remaining 33, 14 could be explained by the resistance genes found (all resistance genes were detected using ONT's Antimicrobial Resistance Mapping Application -ARMA), including mecA found in both MRSA (S16 and S40), sul1 and dfrA12 or dfrA17 genes found in each of two cotrimoxazole resistant E. coli (S1 and S9), aac(3')-IIa (and IIc) in a tobramycin-resistant E. coli (S9) and blaTEM variants found in each of two amoxicillin-resistant E. coli (S1 and S35) and amoxicillin-resistant H. influenzae (S18 and S36). A caveat apropos blaTEM is that ARMA mostly flagged blaTEM-4 when blaTEM-1 was considerably more likely given its vastly greater prevalence and the fact that the isolates remained susceptible to oxyimino-cephalosporins, which are substrates for TEM-4. Another 6/33 cases concerned non-susceptibility to penicillin/b-lactamase inhibitor combinations in isolates where blaTEM or (K. oxytoca) blaOXY was found; resistance here may be associated with these enzymes, but depends on their level of expression, which was not investigated (or measurable) by the present pipeline.
Next, 2/33 instances concerned a specimen where P. aeruginosa (S37) was cultured and found resistant to ceftazidime and piperacillin/tazobactam: blaTEM-4 was found and could explain this phenotype but is unlikely in P. aeruginosa, where b-lactam resistance mostly reflects up-regulation of chromosomal ampC or efflux.
This leaves 11/33 instances where observed resistance was not explained by the genes found. Two of these were amoxicillin-resistant M. catarrhalis (S8 and S26), where genes for the likely BRO b-lactamases are absent from the ARMA databases. Another six, variously including ampicillin and co-trimoxazole resistance in H. influenzae (S7, S18, S36, S39 and S41) and resistances to trimethoprim, ciprofloxacin and fusidic acid in S. aureus (S16) were phenotypes where modification of chromosomal genes is the likely source of resistance, and the relevant sequence data is not analysed by ARMA. Last, there were three instancesone S. aureus resistant to gentamicin (S16) and a K. pneumoniae (S2) resistant to both coamoxiclav and piperacillin/tazobactam but lacking any acquired b-lactamase, where we cannot explain the failure of sequencing to identify a likely mechanism.
Looked at another way, sequencing identified 184 resistance genes across the 41 specimens, based on multiple inclusion when ARMA identified multiple variants of e.g. blaTEM in a specimen. Many of these genes are likely to have originated from the normal flora, as evidenced by the fact that tet(M) was found in 8/12 NRF/NSG specimens as was blaTEM-4, whilst mefA and mel were each found in 9/12 such samples. Other genes, including sul1, dfr determinants and mecA were, however, only found in association with cultivation of an organism with the corresponding resistance. Endogenous resistance genes of cultivated species were widely seen, such as blaOXA-50, catB7 and aph(3')-IIb in P. aeruginosa (S3, S29, S30 and S37) and aac(6')-Ic in S. marcescens (S4 and S13).
The specificity and sensitivity of the developed method for resistance gene detection was not determined as this would have required isolating and sequencing all bacteria (pathogens and commensals) present in the sputum samples, which was beyond the scope of the study.
Reference-based genome assembly
Two samples containing antibiotic resistant bacteria were chosen as examples to generate reference-based genome assemblies directly from the metagenomic data. Assemblies were generated for an MRSA (S16) and an E. coli resistant to amoxicillin, co-amoxiclav and cotrimoxazole (S1). The results were compared with those for undepleted controls after two For the sample positive for resistant E. coli there was 21x genome coverage within two hours, with an assembly of 83 contigs (longest contig = 437kbp and N50=164kbp, data not shown). Genome coverage increased to 165x after 48 hrs with the final E. coli assembly having 78 contigs (longest contig = 473kbp and N50=177kbp). The undepleted sample data only produced 0.3x coverage after 2hrs, which increased to 1.2x genome coverage after 48 hrs sequencing (Figure 2b ).
Time-point analysis
Using the same sample set as for genome assembly, data from the first two hours of sequencing were compared over time for depleted samples and undepleted controls. Within 5 min of sequencing the depleted MRSA sample (S16) had 3x genome coverage compared with the undepleted control (S16-undepleted) at 0.6x coverage (Figure 2c ). The mecA gene was not detected in the undepleted sample after 5 min whereas two mecA gene alignments were detected in the depleted sample by the same time point ( Figure 2d ).
The depleted E. coli sample (S1) had 1.74x genome coverage within 5 min of sequencing whereas the undepleted control (S1-undepleted) had 0.03x (Figure 2e ). This E. coli was resistant to amoxicillin (blaTEM gene), co-amoxiclav (possibly owing to blaTEM if strongly expressed) and co-trimoxazole (sul1 and dfrA17 genes). The blaTEM and dfrA17 genes were not detected in the undepleted sample within two hours of sequencing and only one alignment was detected for sul1. Conversely, all three resistance genes were detected within 20 min of sequencing in the depleted sample and, after two hours, 57 blaTEM, 38 sulf1 and 22 dfrA17 alignments were detected (Figure 2f ).
Cost
The running cost of the optimised pipeline developed in this study was approximately $130 per sample when run in batches of six per flowcell ($546 for singleplex runs) (Supplementary Table 7 ).
Discussion
Current culture-based diagnostics and susceptibility testing, though used for 70 years 29 , have serious limitations as guides for the appropriate clinical management of acute serious infection. This is mainly due to slow sample-to-result turnaround. Rapid, accurate diagnostics are urgently required, so that patients can be prescribed appropriate antibiotics as quickly as possible, potentially improving both outcomes and antimicrobial stewardship.
We developed and tested a novel nanopore sequencing-based clinical metagenomics pipeline for the microbiological investigation (pathogen and antibiotic resistance gene identification) of bacterial LRIs within 6h of clinical diagnosis (assuming the sample is tested immediately).
We began by developing an efficient method for the removal of host DNA from sputum, bronchoalveolar lavage (BAL) and endotracheal aspirates (ETAs). This saponin-based differential lysis method resulted in ~10 3 -fold host DNA depletion without any significant bacterial loss. This high efficiency depends upon the high concentrations of saponin and nuclease buffer salt used. A very high salt buffer (5.5M NaCl) was found to be optimal for nuclease (HL-SAN) digestion of DNA, even though this was far beyond the manufacturer's recommended range for optimum activity. This, combined with a final saponin concentration of 2.2-2.5%, which is higher than used in other saponin based depletion methods 19 , resulted in efficient leukocyte lysis and efficient human DNA depletion. It should be noted that, the same method depletes approx. 10 5 -fold human DNA on average from less inhibitory sample types such as blood and tissue (data not shown). Forty LRI samples were sequenced using the initial Pilot method, which was 91.2% sensitive and 83.3% specific for the detection of respiratory pathogens compared with "gold standard" culture.
The Pilot method was then optimised, by shortening the depletion protocol, introducing bead-beating for improved organism lysis, and reducing the library preparation time by shortening the PCR extension time. The Optimised method was 96.6% sensitive with a turnaround time of six hours. Only one pathogen (1/41) detected by culture was missed (false-negative major error) using the Optimised method (vs. 3/40 using Pilot method); specifically, a P. aeruginosa, which was found by culture in a mixed infection with E. coli.
Possible explanations for missing this pathogen are (i) PCR competition/bias leading to preferential amplification of DNA from the more abundant pathogen or (ii) loss of pseudomonal DNA during host depletion, caused by damaged but viable cells sensitive to saponin lysis. Nevertheless, the mock community experiments demonstrated that common respiratory pathogens including P. aeruginosa were not effected by saponin depletion, the sole notable exception being S. pneumoniae. Under stress, S. pneumoniae is prone to autolysis through the activation of a pneumolysin gene, and this may occur to a portion of the bacteria during the host DNA depletion process 30 (but may also have been caused by autolysis of S. pneumoniae when growing to stationary phase for mock community experiments). S. pneumoniae was correctly identified in five of six patients found by culture to be infected with S. pneumoniae, but it may have been underrepresented in these samples. The time from sample collection to bacterial DNA extraction may be a critical factor for the accurate detection of S. pneumoniae.
The specificity of the Optimised method was significantly lower than the Pilot method (41.6% vs 83.3%). This is likely to be related to the increased sensitivity of the Optimised method (96.5% vs 91.2%). Metagenomic detection of additional pathogens compared to culture was expected as the clinical laboratory routinely dilutes the sample (1/1000) before plating and we used a larger sample volume (400µl vs 10µl). Most (10/17) of the additional organisms detected were potential known pathogens that can also be carried as commensals in the respiratory tract, notably including S. pneumoniae and H. influenzae [31] [32] [33] . Hence, it is likely that the additional pathogens not detected by culture were present in the samples and that culture either failed to detect them or did not report them as significant. However, some of the additional detection observed might be due to bioinformatic misclassification, as k-mer based read classification can be unreliable at the species level, particularly where species in a genus are highly related or share genes. This is particularly important in samples containing high numbers of commensal Streptococci/Haemophilus where a proportion of commensal reads can be misclassified as pathogen reads 34, 35 .
Cut-offs, in terms of number of bacteria per ml of body fluid, are applied in clinical microbiology laboratories for some infections including those of the urinary and respiratory tracts. The same approach is required for metagenomics. The clinical cut-off used for respiratory samples is typically 10 4 pathogens per ml of sample (range 10 3 -10 5 per ml dependent on sample type -achieved by sample dilution) 36 . We routinely applied cut-offs at 1% of classified reads, with a WIMP alignment score ≥20. We chose these cut-offs to: To maximise the impact on patient management, identification of clinically relevant antibiotic resistance genes as well as the infecting pathogen/s is necessary. In this regard the present pipeline has potential but requires refinement. Both MRSA cases were identified by the presence of mecA, with no false positives for this gene. Co-trimoxazole resistance in Enterobacteriaceae was accurately identified with detection of sul and dfr genes and these were not found in H. influenzae, for which resistance is largely mutational 37, 38 . However, genes such as tet(M), mel, mefA and blaTEM were found in 8/12 samples where no pathogen was grown, suggesting presence in the normal or colonising respiratory flora. To overcome this issue, it would be necessary to associate resistance genes to particular organisms. This can be done by examining flanking sequences [39] [40] [41] [42] in the c. 3 kb nanopore reads in cases where a gene is chromosomally inserted, as is usual for transposon borne tet(M) and mefA in streptococci [43] [44] [45] (Supplementary Figure 1) , including S. pneumoniae, but will not determine the source of plasmid-borne resistance genes. Real-time consessus calling for the detection of mutational resistance and chromosomal resistance gene source determination functionality would significantly improve the accuracy of the ARMA output.
An additional advantage of implementing clinical metagenomics (compared to other rapid tests e.g. PCR) is the impact it could have beyond clinical diagnosis. To illustrate this potential, the data generated after 48hrs of sequencing was used to perform reference based pathogen genome assemblies, identifying bacteria beyond species level 17 . Such information is equivalent to reference laboratory typing which is, in the UK, carried out by whole genome sequencing of isolates. The quality of the metagenomic data generated by the method reported here would allow investigations of the emergence and patient-to-patient spread of pathogens and antimicrobial resistance directly from clinical samples in real-time 46, 47 . Currently it would be necessary to run "reference" culture alongside PCR based approaches, otherwise the link to phenotypes would be lost -clinical metagenomics, on the other hand, has the potential to replace routine culture, allowing it to be reserved for more unusual pathogens/resistances.
In conclusion, we report the first rapid clinical metagenomics pipeline for the microbiological 
Methods
Ethics
This study used excess respiratory samples, after routine microbiology diagnostic tests had been performed, from patients with suspected LRIs such as persistent (productive) cough, bronchiectasis, CAP/HAP, cystic fibrosis and exacerbation of chronic obstructive pulmonary disease (COPD, emphysema/chronic bronchitis). Ethical approval was not required as the samples were used for method development, and no patient identifiable information was collected. The only data collected were routine microbiology results, which detailed the pathogen(s) identified and their antibiotic susceptibility profiles.
Routine clinical microbiological investigation
Respiratory samples including sputum, endotracheal secretions and ETAs were treated with sputasol (Oxoid-SR0233) in a 1:1 ratio before being incubated for a minimum of 15 min at 37 °C. Sputasol-treated respiratory samples (10 µl) were inoculated into 5 ml of sterile water and mixed. Following this, 10 µl of sample was streaked onto blood, chocolate and cysteine lactose electrolyte deficient (CLED) agar. BAL samples, they were not treated with sputasol; instead they were centrifuged to concentrate bacterial cells for a minimum of 10 min at 3000 rpm. BALs did not undergo further dilution and were streaked directly onto the agar plate.
Depending on clinical details and the source of the specimen, other agar plates (including sabouraud, mannitol salt and Burkholderia cepacia selective agar) were additionally used.
All inoculated agar plates were incubated at 37 C overnight and then examined for growth with the potential for re-incubation up to 48 hours. If any significant organism was grown then antibiotic susceptibility testing by agar diffusion using EUCAST methodology was performed. The laboratory's Standard Operating Procedure is based on the Public Health England UK Standards for Microbiology Investigations B 57: Investigation of bronchoalveolar lavage, sputum and associated specimens 36 .
Sample collection and storage
The excess respiratory samples (sputa, ETA, BAL) were collected after culture and susceptibility testing at Norfolk and Norwich University Hospitals (NNUH) Microbiology Department (described above) and stored at 4 °C prior to testing. They were indicated by clinical microbiology to contain bacterial pathogen(s), NRF or to have yielded NSG. Forty samples (n=34 positive and n=6 NRF samples, comprising 34 sputa, four BALs and two ETAs) were used to test the first 'Pilot" iteration of the diagnostic pipeline and another 41 (n=29 suspected LRI, n=9 NRF and n=3 NSG samples, comprising 38 sputa, one BAL and two ETAs) to test the Optimised pipeline.
First iteration of the diagnostic pipeline (Pilot method): Host DNA Depletion
Respiratory samples (400 µl) were centrifuged at 8000 xg for 5 min, after which the supernatant was carefully removed and the pellet resuspended in 250 µl of PBS, any pellet >50 µl was diluted one in four and re-centrifuged. The saponin-based differential lysis method was modified from previously reported saponin methods 48, 49 added to the sample, which next was incubated for a further 15 min at 37°C with shaking at 800 RPM. Finally, the host-DNA depleted samples were washed three times with decreasing volumes of PBS (300 µl, 150 µl, 50 µl). After each wash, the sample was centrifuged at 6000 xg for 3 min, the supernatant discarded and the pellet resuspended in PBS.
Pilot method: Bacterial Lysis and DNA Extraction
After the final wash step of the host depletion, the pellet was resuspended in 380 µl of bacterial lysis buffer (Roche UK-4659180001) and 20 µl of proteinase K (>600mAu/ml) (Qiagen -19133) was added before incubation at 65°C for 10 min with shaking at 800 RPM (on an Eppendorf Thermomixer). Nucleic acid was then extracted from samples using the Roche MagnaPure Compact DNA_bacteria_V3_2 protocol (MagNA pure compact NA isolation kit I, Roche UK-03730964001) on a MagNA Pure Compact machine (Roche UK-03731146001).
Optimised method: Host DNA Depletion (Figure 1)
The optimized method sought to improve and shorten some steps. Specifically, after the first 5 min centrifugation at 8000 x g, up to 50 µl of supernatent was left so as to not disturb the pellet (final saponin conc. 2.2-2.5%). Instead of performing two rounds of host DNA digestion, the amount of HL-SAN DNase was increased up to 10 µl and a single incubation of 15 min at 37 °C was carried out with shaking at 800 RPM on an Eppendorf Thermomixer.
Finally, the number of washes was reduced to two with increasing volumes of PBS (800 µl and 1 ml).
Optimised method: Bacterial Lysis and DNA Extraction (Figure 1)
After the final wash, the pellet was re-suspended in 500 µl of bacterial lysis buffer (Roche for Pilot method samples and the first two hours of data for all Optimised method samples. To the PCR mix, 2 µl of DNA template and nuclease-free water to a total volume of 20 µl were added. The qPCR conditions were: pre-incubation at 95°C for 5 min, amplification for 40 cycles at 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec, with a final extension at 72°C for 5 min. Melt curves analysis was performed at 95°C for 5 sec, 65°C for 1 min, ramping to 95°C at 0.03°C/s in continuous acquisition mode, followed by cooling to 37°C. 
MinION Library Preparation and Sequencing
Quantitative PCR (qPCR) assays
Example Limit of detection
Mock community experiments
Clinical isolates from respiratory samples were used to generate a mock community consisting of S. pneumoniae, K. pneumoniae, H. influenzae, S. maltophilia and P. aeruginosa. E. coli and S. aureus strains were also included (H141480453 and NCTC 6571 respectively).
Pathogens (E. coli and S. aureus in 10 ml Luria-Broth and K. pneumoniae, P. aeruginosa and S. maltophilia in 10 ml Tryptic Soy Broth (TSB)) were cultured overnight at 37°C with shaking at 180 RPM. H. influenzae (in 10 ml TSB) and S. pneumoniae (in 10 ml Brain Heart Infusion Broth) were cultured statically at 37°C with 5% CO2 in an aerobic incubator. Cultured pathogens were then spiked into an NRF sample (~10 8 cfu/ml per pathogen). The spiked samples were then tested in triplicate with the Optimised method, to determine if saponin depletion resulted in any inadvertent lysis of pathogens and loss of their DNA. All spiked samples were processed alongside undepleted controls. Probe or SYBR Green-based qPCR assays were used to determine the relative quantity of each spiked pathogen in depleted and undepleted spiked sputum samples.
Pathogen identification and antibiotic resistance gene detection
The EPI2ME Antimicrobial Resistance pipeline (ONT, versions 2.47.537208-2.52.1202033) was used for initial analysis of MinION data for the identification of bacteria present in the sample and any associated antimicrobial resistance genes. Within this pipeline, WIMP (What's in my Pot -which utilises 'Centrifuge' kmer-based read identification 50 ) was used for respiratory pathogen identification and ARMA (Antimicrobial Resistance Mapping Application -which utilised the CARD database 51 ) for antibiotic resistance gene detection.
Potential pathogen(s) were reported if the number of reads accounted for ³1% of microbial reads and with a WIMP alignment score ≥20. Antibiotic resistance genes were reported if >1 gene alignment was present using the 'clinically relevant' parameter within ARMA. This currently only reports resistance genes, acquired and chromosomal, but does not report resistance mutations/SNPs.
Bacterial genome assembly
Genome assembly was performed first using Fast5-to-Fastq to remove reads shorter than 2000 bp and with a mean quality score lower than seven (https://github.com/rrwick/Fast5-to-Fastq). Porechop was used to remove sequencing adapters in the middle or the ends of each read, and re-identification of barcodes was carried out for each multiplexed sample (v0.2.3) (https://github.com/rrwick/Porechop). Filtered reads were aligned to a reference genome (chosen based on WIMP classification of pathogen reads) using Minimap2 with default parameters for ONT long-read data (v2.6-2.10) 52 . Finally, Canu was used to assemble mapped reads into contigs using this long-read sequence correction and assembly tool (v1.6) 53, 54 . BLAST Ring Image Generator (BRIG) was used for BLAST comparisons of the genome assemblies generated 55 .
Human DNA removal
Human DNA reads were removed from basecalled FASTQ files using Minimap2 to align to the human hg38 genome (GCA_000001405.15 "soft-masked" assembly) prior to Epi2ME analysis. Only unassigned reads were exported to a bam file using Samtools (-f 4 parameter). Non-human reads were converted back to FASTQ format using bam2fastx.
These FASTQ files were processed for pathogen identification using WIMP and antibiotic resistance gene detection with ARMA. Table 1: Pilot metagenomic pipeline output compared to routine microbiology culture results. instances
Figure legends
Tables
Principal examples
Gene recorded in a specimen with no pathogen grown 56
Mostly tet, mef mel, blaTEM-4 determinants, likely to be associated with normal flora Genes unlikely to be from species grown by the laboratory 51
Mostly gram-positive-associated genes when a gram-negative organism was grown, or vice versa: commonly including tet(M) and mefA
Gene endogenous in species 24
Mostly efflux components; also blaOXA-50, aph(3')-IIb and catB7 from P. aeruginosa and aac(6')-Ic from S. marcescens Partial match to observed resistances 15
Instances where blaTEM was found but where MinION flagged an ESBL-encoding variant, usually blaTEM-4, but where the phenotype indicated only a classical penicillinase, without oxyiminocephalosporin resistance
Possibly present, but relevant drug not tested by clin lab 15
Commonly (i) where tet(C) found but lab tested doxycycline, which is not a substrate for this pump, or (ii) where streptomycin, kanamycin and macrolide determinants were found in gramnegative bacteria but these drugs were not tested, as not relevant to therapy.
Does not match phenotype of isolate 11
Mostly where blaTEM (as blaTEM-4) was recorded but the isolate (commonly H. influenzae) was susceptible to penicillins as well as cephalosporins, or where tet(M) was found together with a tetracycline-susceptible S. aureus
Match to observed R 10
Variously including mecA in MRSA, blaTEM in Enterobacteriaceae and H. influenzae, also sul1 and dfr determinants for E. coli Unlikely match to observed phenotype 2 P. aeruginosa with blaTEM resistant to piperacillin/tazobactam and ceftazidime -see text Total 184
